These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21103738)

  • 1. VEGF gene therapy for angiogenesis in refractory angina: phase I/II clinical trial.
    Kalil RA; Salles FB; Giusti II; Rodrigues CG; Han SW; Sant'Anna RT; Ludwig E; Grossman G; Prates PR; Sant'anna JR; Teixeira Filho GF; Nardi NB; Nesralla IA
    Rev Bras Cir Cardiovasc; 2010; 25(3):311-21. PubMed ID: 21103738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High doses of vascular endothelial growth factor 165 safely, but transiently, improve myocardial perfusion in no-option ischemic disease.
    Giusti II; Rodrigues CG; Salles FB; Sant'Anna RT; Eibel B; Han SW; Ludwig E; Grossman G; Prates PR; Sant'Anna JR; Filho GF; Markoski MM; Nesralla IA; Nardi NB; Kalil RA
    Hum Gene Ther Methods; 2013 Oct; 24(5):298-306. PubMed ID: 23944648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial.
    Kastrup J; Jørgensen E; Rück A; Tägil K; Glogar D; Ruzyllo W; Bøtker HE; Dudek D; Drvota V; Hesse B; Thuesen L; Blomberg P; Gyöngyösi M; Sylvén C;
    J Am Coll Cardiol; 2005 Apr; 45(7):982-8. PubMed ID: 15808751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF 165 gene therapy for patients with refractory angina: mobilization of endothelial progenitor cells.
    Rodrigues CG; Plentz RD; Dipp T; Salles FB; Giusti II; Sant'Anna RT; Eibel B; Nesralla IA; Markoski M; Beyer NN; Kalil RA
    Arq Bras Cardiol; 2013 Aug; 101(2):149-53. PubMed ID: 23842797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations.
    Povsic TJ; Henry TD; Ohman EM; Pepine CJ; Crystal RG; Rosengart TK; Reinhardt RR; Dittrich HC; Traverse JH; Answini GA; Mokadam NA
    Am Heart J; 2021 Nov; 241():38-49. PubMed ID: 34224684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intramyocardial injection of autologous bone marrow-derived mononuclear cells on perfusion, function, and viability in patients with drug-refractory chronic ischemia.
    Beeres SL; Bax JJ; Dibbets P; Stokkel MP; Zeppenfeld K; Fibbe WE; van der Wall EE; Schalij MJ; Atsma DE
    J Nucl Med; 2006 Apr; 47(4):574-80. PubMed ID: 16595489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of response to intramyocardial bone marrow cell treatment in patients with refractory angina and chronic myocardial ischemia.
    Rodrigo SF; van Ramshorst J; Mann I; Leong DP; Cannegieter SC; Al Younis I; Dibbets-Schneider P; de Roos A; Fibbe WE; Zwaginga JJ; Bax JJ; Schalij MJ; Beeres SL; Atsma DE
    Int J Cardiol; 2014 Aug; 175(3):539-44. PubMed ID: 25023791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease--12-month follow-up: angiogenic gene therapy.
    Sarkar N; Rück A; Källner G; Y-Hassan S; Blomberg P; Islam KB; van der Linden J; Lindblom D; Nygren AT; Lind B; Brodin LA; Drvota V; Sylvén C
    J Intern Med; 2001 Nov; 250(5):373-81. PubMed ID: 11887971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.
    Stewart DJ; Hilton JD; Arnold JM; Gregoire J; Rivard A; Archer SL; Charbonneau F; Cohen E; Curtis M; Buller CE; Mendelsohn FO; Dib N; Page P; Ducas J; Plante S; Sullivan J; Macko J; Rasmussen C; Kessler PD; Rasmussen HS
    Gene Ther; 2006 Nov; 13(21):1503-11. PubMed ID: 16791287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina--final 3-year follow-up.
    Mathiasen AB; Haack-Sørensen M; Jørgensen E; Kastrup J
    Int J Cardiol; 2013 Dec; 170(2):246-51. PubMed ID: 24211066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.
    Fuchs S; Dib N; Cohen BM; Okubagzi P; Diethrich EB; Campbell A; Macko J; Kessler PD; Rasmussen HS; Epstein SE; Kornowski R
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):372-8. PubMed ID: 16892433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study.
    Gyöngyösi M; Khorsand A; Zamini S; Sperker W; Strehblow C; Kastrup J; Jorgensen E; Hesse B; Tägil K; Bøtker HE; Ruzyllo W; Teresiñska A; Dudek D; Hubalewska A; Rück A; Nielsen SS; Graf S; Mundigler G; Novak J; Sochor H; Maurer G; Glogar D; Sylven C
    Circulation; 2005 Aug; 112(9 Suppl):I157-65. PubMed ID: 16159809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial.
    Favaloro L; Diez M; Mendiz O; Janavel GV; Valdivieso L; Ratto R; Garelli G; Salmo F; Criscuolo M; Bercovich A; Crottogini A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):899-906. PubMed ID: 22777825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
    Losordo DW; Vale PR; Symes JF; Dunnington CH; Esakof DD; Maysky M; Ashare AB; Lathi K; Isner JM
    Circulation; 1998 Dec 22-29; 98(25):2800-4. PubMed ID: 9860779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial Doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris.
    Sylvén C; Sarkar N; Rück A; Drvota V; Hassan SY; Lind B; Nygren A; Källner Q; Blomberg P; van der Linden J; Lindblom D; Brodin LA; Islam KB
    Coron Artery Dis; 2001 May; 12(3):239-43. PubMed ID: 11352080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD).
    Kukuła K; Chojnowska L; Dąbrowski M; Witkowski A; Chmielak Z; Skwarek M; Kądziela J; Teresińska A; Małecki M; Janik P; Lewandowski Z; Kłopotowski M; Wnuk J; Rużyłło W
    Am Heart J; 2011 Mar; 161(3):581-9. PubMed ID: 21392615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac shock wave therapy improves myocardial perfusion and preserves left ventricular mechanics in patients with refractory angina: A study with speckle tracking echocardiography.
    Duque AS; Ceccon CL; Mathias W; Majesky JD; Gowdak LH; Sbano JCN; Cesar LAM; Abduch MC; Lima MSM; Dourado PMM; Cruz CBBV; Tsutsui JM
    Echocardiography; 2018 Oct; 35(10):1564-1570. PubMed ID: 29962073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial.
    van Ramshorst J; Bax JJ; Beeres SL; Dibbets-Schneider P; Roes SD; Stokkel MP; de Roos A; Fibbe WE; Zwaginga JJ; Boersma E; Schalij MJ; Atsma DE
    JAMA; 2009 May; 301(19):1997-2004. PubMed ID: 19454638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated Intramyocardial Bone Marrow Cell Injection in Previously Responding Patients With Refractory Angina Again Improves Myocardial Perfusion, Anginal Complaints, and Quality of Life.
    Mann I; Rodrigo SF; van Ramshorst J; Beeres SL; Dibbets-Schneider P; de Roos A; Wolterbeek R; Zwaginga JJ; Fibbe WE; Bax JJ; Schalij MJ; Atsma DE
    Circ Cardiovasc Interv; 2015 Aug; 8(8):. PubMed ID: 26259770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients.
    Reilly JP; Grise MA; Fortuin FD; Vale PR; Schaer GL; Lopez J; VAN Camp JR; Henry T; Richenbacher WE; Losordo DW; Schatz RA; Isner JM
    J Interv Cardiol; 2005 Feb; 18(1):27-31. PubMed ID: 15788051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.